Perspective from Philip Abbosh, MD, PhD A urinary DNA methylation test showed potential for detecting high-grade or invasive bladder cancer, according to results of a prospective multicenter study.

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer ... for BCG-unresponsive NMIBC with high-grade papillary disease, BCG treatment ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC ... with or without ...

Protara Therapeutics’ leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more ...

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

The FDA has approved Imfinzi® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with MIBC.

AstraZeneca's treatment for adults with muscle-invasive bladder cancer was approved in the U.S.

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...